Not currently recruiting at University of California Health
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Davis UCSD
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Stichting European Myeloma Network
- ID
- NCT05243797
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 1594 study participants
- Last Updated